Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47

Benzinga Newsdesk www.benzinga.com Positive 77.3%

Neg 0% Neu 0% Pos 77.3%

Jefferies analyst Maury Raycroft maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $39 to $47.